

RESMED ACQUIRES DUTCH DISTRIBUTOR

SYDNEY, Australia, December 15, 2004 – ResMed Inc. (ASX: RMD) announced today that it has acquired the assets of substantially all of Resprecare Medical B.V., its exclusive distributor in the Netherlands. ResMed will now sell respiratory products direct to the Dutch market through ResMed Nederland B.V. Rene van den Heuvel, the principal owner of Resprecare Medical, will serve as the Managing Director of ResMed Nederland. The acquisition is not expected to have a significant impact on ResMed's revenues or earnings in fiscal year 2005.

“This acquisition of our exclusive distributor fits our strategy for ongoing expansion of our international operations. We have been particularly successful in selling directly in Europe, which improves our understanding of local markets as well as our relationships with physicians and payors. Most importantly, these acquisitions bring us closer to patients and allow us to better respond to their needs,” stated Peter C. Farrell, PhD, Chairman and Chief Executive Officer.

About ResMed

ResMed is a leading manufacturer of medical equipment for the diagnosis, treatment, and management of sleep-disordered breathing, which is estimated to affect approximately 43 million Americans. We are dedicated to improving awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing and to developing innovative technology to improve the lives of those who suffer from this condition. For more information on ResMed, visit www.resmed.com.

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These include statements regarding international expansion and improving margins. These forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission. Those reports are available on the Company's Web site.

Contact:

Hillary Theakston
Director of Investor Relations
Tel. +1 (858) 746-2610
Email: hillaryt@resmed.com